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Abstract
Background: Although there is a growing body of evidence showing that patients with type 2 diabetes mellitus 
(T2DM) have poor glycemic control in general, it is not clear whether T2DM patients with pre-existing cardiovascular 
diseases (CVD) are more or less likely to have good glycemic control than patients without pre-existing CVD. Our aim 
was to examine the degree of glycemic control among T2DM patients in Europe with and without pre-existing CVD.
Methods: This is a matched cohort study based on a multi-center, observational study with retrospective medical 
chart reviews of T2DM patients in Spain, France, United Kingdom, Norway, Finland, Germany, and Poland. Included 
patients were aged >= 30 years at time of diagnosis of T2DM, had added a SU or a PPARγ agonist to failing metformin 
monotherapy (index date) and had pre-existing CVD (cases). A control cohort with T2DM without pre-existing CVD 
was identified using 1:1 propensity score matching. With difference-in-difference approach, logistic and linear 
regression analyses were applied to identify differences in glycemic control by CVD during the follow up period, after 
controlling for baseline demographics, clinical information, and concurrent anti-hyperglycemic medication use.
Results: The percentage of case patients with adequate glycemic control relative to control patients during the 1st, 
2nd, 3rd, and 4th years after the index date was 19.9 vs. 26.5, 16.8 vs. 26.5, 18.8 vs. 28.3, and 16.8 vs. 23.5 respectively. 
Cases were significantly less likely to have adequate glycemic control (odds ratio: 0.62; 95% confidence interval: 0.46-
0.82) than controls after adjusting for baseline differences, secular trend, and other potential confounding covariates.
Conclusions: T2DM patients with pre-existing CVD tended to have poorer glycemic control than those without pre-
existing CVD, all other factors being equal. It suggests that clinicians may need to pay more attention to glycemic 
control among T2DM patients with CVD.
Background
Patients with type 2 diabetes mellitus (T2DM) are at an
increased risk of developing vascular complications. Car-
diovascular diseases (CVD) are a major concern consid-
ering that the risk of cardiovascular death in patients with
T2DM is double the risk of individuals without diabetes
[1,2]. Patients with diabetes also have the same risk of
cardiovascular death as patients with a history of myocar-
dial infarction and no diabetes [1,3].
The literature does not seem to show a universally con-
sistent relationship between glycemic control and CVD,
despite the documented beneficial effect of glycemic con-
trol on microvascular complications [4-6]. The meta-
analysis conducted by Selvin and colleagues [7] reviewed
13 prospective cohort studies, and the pooled results
indicated that chronic hyperglycemia was associated with
cardiovascular disease in patients with T2DM. Another
meta-analysis [8] based on 8 randomized controlled trials
found a similar relationship and concluded that glycemic
control reduces the incidence of cardiovascular events in
T2DM. A prospective epidemiological analysis based on
the Heart Outcome Prevention Evaluation (HOPE) study
also identified a significant relationship between glycemic
level and incident cardiovascular events [9]. Most
recently, Ray et al conducted a meta-analysis of five pro-
spective randomized controlled trials and the results
indicated that intensive glycemic control has cardiovas-
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cular benefits compared with standard treatment for
individuals with T2DM [10].
In contrast, results from several other published studies
suggest that additional research is necessary to further
clarify the relationship between glycemic control and
CVD [11,12]. The ACCORD (Action to Control Cardio-
vascular Risk in Diabetes) trial with 3.5-years follow-up
found that the use of intensive therapy for glycemic con-
trol in patients with T2DM did not reduce cardiovascular
events but increased mortality compared to standard
therapy [13]. Meanwhile, the ADVANCE (Action in Dia-
betes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation) trial with 5-
years follow-up also did not find a significant reduction in
cardiovascular events in T2DM patients with intensive
treatment for glycemic control compared to patients with
standard therapy [14]. Similarly, the results from another
retrospective cohort study suggest that there is little or no
relationship between glycemic level and recurrent cardio-
vascu la r eve n ts  [11] .  Clear ly , it  is  st il l ea r l y t o c la im  a
definitive monotonic association between glycemic con-
trol and CVD, and additional research is warranted.
While studying this hyperglycemia-CVD relationship
in T2DM, existing studies have been primarily focused on
the impact of glycemic control on CVD outcomes. Few
studies have addressed this relationship from a different
angle. Although there is a growing body of evidence
s h o w i n g  t h a t  p a t i e n t s  w i t h  T 2 D M  h a v e  poo r  g l y c e m i c
control in general, it is not clear whether T2DM patients
w i t h  p r e - e x i s t i n g  CV D  a r e  m o r e  o r  l e s s  l i k e l y  t o  h a v e
good glycemic control than patients without pre-existing
CVD. The purpose of the current study was to examine
the degree of glycemic control among T2DM patients in
Europe with and without pre-existing CVD.
Methods
Data source
The Real-Life Effectiveness and Care Patterns of Diabetes
Management (RECAP-DM) study is a European multi-
center based, epidemiological and naturalistic observa-
tional study for patients with T2DM. Using retrospective
clinical chart review and patient survey at the point of
visit, the RECAP-DM study was conducted in clinical
practice settings in seven European countries including
Spain, France, United Kingdom, Norway, Finland, Ger-
many, and Poland. At the beginning of the study, a mailed
invitation was sent to randomly selected physicians ask-
ing if they would be willing to participate in the study.
The participating physicians included endocrinologists,
diabetologists, general practitioners, and internalists.
The RECAP-DM included patients aged 30 years or
older at time of diagnosis of T2DM, who had added a SU
or PPARγ agonist (glitazones) to failing metformin
monotherapy on a date from January 2001 to January
2006, which was defined as the index date (Figure 1).
Patient enrollment in the RECAP-DM occurred during
regular visits within the period from June 2006 to Febru-
ary 2007. Eligible patients were required to have at least
one hemoglobin A1c (HbA1c) measurement in the 12-
months prior to the visit date. Patients were excluded
from the RECAP-DM if they had type 1 diabetes, were
pregnant women with gestational diabetes, or had diabe-
tes secondary to other factors (such as malnutrition,
infection, and surgery). Patients who were unable to com-
plete the questionnaires or were participating in other
clinical studies were excluded as well. To our knowledge,
RECAP-DM is the only study applying a consistent meth-
odology across multiple European countries focusing on
patients with T2DM who also received combination oral
diabetes medications [15,16].
Study Design and Variables
The current study was a matched cohort study using the
RECAP-DM sample. The case cohort included those who
had pre-existing CVD (i.e., with onset date prior to the
index date) within the RECAP-DM and the control
cohort was selected among those who had no pre-exist-
ing CVD. CVD included ischemic heart disease, myocar-
dial infarction (MI), stroke, and peripheral vascular
disease based on ICD-9 codes. Patient baseline informa-
tion was collected and included patient demographic
characteristics and clinical information during the 6-
months prior to the index date.
The primary outcome of focus was HbA1c at baseline as
well as during the study period (from index date to
patient visit date - Figure 1). Another outcome of interest
was the proportion of patients with adequate glycemic
control, defined as HbA1c < 6.5% by the 2005 Interna-
tional Diabetes Federation [17]. To evaluate the pattern of
glycemic control over time, patients were grouped based
on time, categorized in years from the index date to the
visit date. For each year, only samples with HbA1c mea-
sures within the year were included. If there were multi-
ple HbA1c measures within the year for a patient, the
most recent measurement relative to the visit date was
selected.
Figure 1 Diagram for patient selection.
January 2001
Patient Visit Date Index Date
(Initial addition of a sulphonylurea or glitazone to metformin monotherapy)
Patient visit period 
(June 2006 to February 2007)
Study Period
(From Index Date to patient Visit Date)  
January 2006
Eligibility screening period 
Baseline Period
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Other baseline covariates that were controlled for in the
analysis included age, gender, ethnicity, duration of
T2DM, alcohol consumption status, physical activity fre-
quency, country location, body mass index, physician
specialty, and duration of metformin use. The participat-
ing physicians included endocrinologists, diabetologists,
general practitioners, and internalists for RECAP-DM.
Endocrinologists or diabetologists may be more acutely
aware of disease management needs relative to general
practitioners or internalists, which could influence the
glycemic outcomes of their patients. Thus, a classification
of endocrinologists/diabetologists versus general practi-
tioners/internalists was applied for physician specialty.
The index medication use of SU versus glitazones was
controlled for as well.
During the study period, patients may not be persistent
in their use of the index medication. The treatment pat-
tern could change, which would confound the evaluation
of the relationship between baseline CVD and the HbA1c
at various time. Therefore, the concurrent anti-hypergly-
cemic medication treatment at the time of the HbA1c
measurement was also captured and controlled for in the
analysis. If the date of the HbA1c  measurement was
between the starting and stop dates of a certain anti-
hyperglycemic medication, that medication was defined
as the concurrent treatment at the time of that HbA1c
measurement. In the analyses, the concurrent treatment
was categorized into 6 groups: metformin+SU combina-
tion therapy, metformin+glitazones combination therapy,
SU monotherapy, glitazones monotherapy, metformin
monotherapy, and therapies with insulin. There might be
slight overlap between certain treatment types, such as
the combination therapy and therapies with insulin.
Thus, the estimated effect on any treatment type
reflected the marginal difference between patients with
that therapy and those without any of the 6 aforemen-
tioned treatments.
Statistical Analyses
Descriptive analysis was conducted to summarize patient
demographic characteristics and clinical information at
baseline. The variables were compared between patients
with and without CVD at baseline. T-tests were used for
continuous variables and chi-square tests were calculated
for categorical variables.
The propensity score method was used to match case
and control cohorts. A logistic regression was first used
to predict the probabilities of pre-existing CVD using a
list of baseline characteristics. The variable selection was
based on the idea [18,19] that it was the variables having
an effect on or associated with the HbA1c and blood glu-
cose instead of CVD that needed to be matched so that
the impact of pre-existing CVD on HbA1c can be properly
evaluated. The variables that did not have an effect on
HbA1c outcomes were not included.
The case and control cohorts were 1:1 matched by pro-
pensity scores using the greedy matching algorithm [20].
That is, once a control is matched, the control is not
reconsidered. The algorithm makes "best" matches first
and "next-best" matches next, in a hierarchical sequence
until no more matches can be made. Best matches are
those with the highest digit match on propensity score.
First, controls were matched to cases on 8 digits of the
propensity score. For those that did not match, controls
were then matched to cases on 7 digits of the propensity
score. The algorithm proceeds sequentially to the lowest
digit match on propensity score (1 digit).
The trends of glycemic control and the impact of pre-
existing CVD on glycemic control were analyzed using a
difference-in-difference (DID) strategy [21,22]. The DID
approach compares the pre- and post-index difference in
glycemic control among T2DM patients with pre-existing
CVD, with the pre- and post-index difference in glycemic
control among T2DM patients without pre-existing
CVD. Thus, the DID strategy allows one to identify the
effect attributable to pre-existing CVD after accounting
for any possible secular trend.
Logistic and linear regression analyses were applied to
assess any relationship between pre-existing CVD and
glycemic control (HbA1c<6.5% yes/no) or HbA1c value.
For the DID approach, 5 additional binary variables were
included in the regression analyses indicating the 5 post-
index time periods (<1 year, 1-2 years, 2-3 years, 3-4
years, and ≥4 years from the index date). These were used
to capture the time effect on outcomes. Five interaction
terms for CVD with the 5 post-index periods were
included in the model, capturing the potential differential
CVD-effects on glycemic control over time.
As a sensitivity analysis, the time effect was assumed
linear after the index date. Thus, the analytical model was
reduced where only 2 time variables were included, one
b i n a ry  va ria b l e  i n d i ca t i n g  t h e  t i m e  o f  po s t  v e r s u s  p r e -
index and another continuous variable representing the
actual time from the index date measured in years. Subse-
quently, for the sensitivity analysis, 2 interaction terms
were included to capture the potential differential CVD-
effects on glycemic control. Robust variance estimator
was used to account for multiple observations per patient
and correlation within subjects.
In our study, several covariates had missing or
unknown data for certain patients. Although the missing
for each covariate is trivial, the final sample size would
have been reduced to less than half of the total if the com-
plete case analysis approach was adopted. We used the
multiple imputation procedure to impute missing values
of each covariate, assuming that the data are multivariate
normally distributed and the missing data are missing atFu et al. Cardiovascular Diabetology 2010, 9:15
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random. The procedure used the Markov Chain Monte
Carlo method with a single chain to create imputations.
Results
This study had 1942 T2DM patients with complete ques-
tionnaire information for CVD at the baseline. There
were 406 patients (20.9%) with CVD and 1536 patients
without CVD before the index date. Among those with
pre-existing CVD, ischemic heart disease was the most
prevalent (272 patients, 67%), followed by MI (103
patients, 25%), peripheral vascular disease (98 patients,
24%), and stroke (47 patients, 12%).
The descriptive comparisons of all the demographics
and baseline clinical information between patients with
and without pre-existing CVD are shown in Table 1.
Compared to patients without CVD at the baseline, those
with CVD were significantly older and more likely to be
male. UK and Poland had more patients whereas Spain
and Finland had fewer patients with pre-existing CVD in
the sample. The percentage of the sample with adequate
glycemic control (HbA1c<6.5%) was significantly lower
for those with pre-existing CVD compared to those with-
out. There were significantly more patients with pre-
existing CVD who added SU instead of glitazones to met-
formin monotherapy at the index date compared to
patients without CVD.
Patient characteristics after propensity score 1:1 match-
ing are also listed in Table 1, where the created case and
control cohorts were comparable regarding baseline
characteristics. Of the 394 patients with pre-existing
CVD, 65% were male, mean (standard deviation) age and
duration of T2DM was 64.0 (9.0) and 6.0 (5.0) years,
respectively.
Figure 2 shows the percentage of the sample with
HbA1c<6.5% (adequate glycemic control) and the average
HbA1c over time. The percentage of the case cohort with
adequate glycemic control relative to the control cohort
during the 1st, 2nd, 3rd, and 4th years after index date
was 19.9 vs. 26.5, 16.8 vs. 26.5, 18.8 vs. 28.3, and 16.8 vs.
23.5 respectively. The sample sizes remained almost iden-
tical between the case and control cohorts although both
decreased over time owing to attrition.
None of the interaction terms between pre-existing
CVD and the post-index time periods in the regression
analyses were statistically significant, indicating no differ-
ential CVD-effects on glycemic control over time. Thus,
the final regression models excluded these interaction
terms. The results from the final regressions are reported
in Table 2 and indicate that patients with pre-existing
CVD were significantly less likely to have adequate glyce-
mic control (odds ratio: 0.62; 95% confidence interval:
0.46-0.82) than those without pre-existing CVD after
controlling for other potential confounding covariates.
The effect was not significant when HbA1c value was the
outcome of focus. The almost identical results for CVD
between regressions on the same outcome variable
implies that treating the post-index time continuously or
categorically year-by-year had little difference on the
coefficient of interest. All time covariates were signifi-
cant, indicating that the likelihood of adequate glycemic
control was higher for post-index outcomes compared to
their pre-index values. This demonstrates the effective-
ness of the post-index medication treatment regardless of
the patient cohorts. Such a finding is important for the
original RECAP-DM study.
Discussion
Our study results suggest that there is a significant differ-
ence in the percentage of T2DM patients with adequate
glycemic control (HbA1c < 6.5%) in those with and with-
out pre-existing CVD. Using a seven-country European
sample, the current study provides important empirical
evidence about the degree of glycemic control among
T2DM patients with and without pre-existing CVD. Most
of the previous research has focused on CVD resulting
from poor glycemic control as the outcome of interest.
The present study is unique in that we used HbA1c value
and adequate glycemic control as the outcomes of inter-
est and studied CVD as a baseline factor. Due to the
design of the RECAP-DM study, the temporal relation-
ship between CVD and glycemic control is apparent.
The premise of the study is that, other things being
equal, patients with pre-existing CVD should have better
glycemic control due to increased risk of future cardio-
vascular events. Our study showed that patients at
increased risk of cardiovascular events are not controlled
any better than patients with lower risk (and in fact their
control is worse). This implies an important unmet medi-
cal need. The reasons for the observed difference in gly-
cemic controls between the two groups remain a
question. We have adjusted for the concurrent anti-
hyperglycemic medication use in the analyses. Thus, the
treatment difference might not be a contributor. How-
ever, the literature indicates that physicians taking care of
diabetic patients with CVD might face multiple obstacles
for obtaining adequate glycemic control. Treatment
guidelines suggest more stringent control of blood pres-
sure and lipids, in addition to the blood glucose control.
There are a variety of additional medications (e.g., anti-
platelet medications) that are recommended to prevent
future CVD events. More importantly, there is evidence
that glycemic control may not be the most significant fac-
tor for preventing another CVD event [23,24]. Diabetic
patients with CVD may have conditions (e.g., congestive
heart failure) that prevent the use of certain anti-hyperg-
lycemic agents. Additionally, due to concomitant condi-Fu et al. Cardiovascular Diabetology 2010, 9:15
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Table 1: Patients characteristics by cardiovascular diseases at baseline (before and after propensity score 1:1 matching)
Before Matching After Matching
Variables Mean (S.D.) P-value Mean (S.D.) P-value
With CVD 
(N = 406)
Without CVD 
(N = 1536)
With CVD 
(N = 394)
Without CVD 
(N = 394)
SU added at index 80.8% 73.6% 0.003 - - -
Glitazones added at index 19.2% 26.4% - - -
Demographics
Age (years) 64.3 (9.2) 59.5 (10.5) < 0.0001 64.0 (9.0) 63.9 (10.1) 0.96
Male 65.5% 51.3% < 0.0001 65.0% 70.3% 0.11
Caucasian 98.0% 96.7% 0.17 98.0% 98.4% 0.68
Duration of diabetes (years) 6.1 (5.2) 5.6 (4.8) 0.09 6.0 (5.0) 6.1 (5.0) 0.99
Never used alcohol 27.6% 30.4% 0.29 27.9% 26.1% 0.57
Physical Activity
No regular activity 39.1% 34.6% 0.11 37.6% 39.5% 0.58
< 3 times/week 39.1% 39.7% 0.83 41.0% 36.5% 0.12
≥ 3 times/week 21.9% 25.7% 0.12 21.4% 24.0% 0.34
Country
Spain 15.8% 28.1% < 0.0001 16.2% 15.0% 0.62
France 6.9% 8.1% 0.43 7.1% 6.9% 0.89
UK 26.6% 16.9% < 0.0001 26.7% 26.4% 0.94
Norway 3.0% 3.4% 0.67 3.1% 4.8% 0.20
Finland 7.4% 10.7% 0.049 7.6% 10.2% 0.21
Germany 17.7% 21.4% 0.10 18.3% 19.8% 0.59
Poland 22.7% 11.5% < 0.0001 21.1% 17.0% 0.15Fu et al. Cardiovascular Diabetology 2010, 9:15
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tions and medication interactions, these patients may be
at particularly high risk for hypoglycemia, which may
cause even more morbidity than mild hyperglycemia in
the short term. Obviously, more research is needed in this
area.
Our analyses have several strengths. First, this study
used the RECAP-DM sample, which was recruited using
a consistent methodology across seven European coun-
tries focusing on T2DM patients who received combina-
tion oral diabetes treatment. Second, we applied the DID
strategy in the analysis design. This approach cancelled
out both the secular trend and the baseline group differ-
ence while evaluating HbA1c differences between patients
with and without pre-existing CVD in the follow-up
period. Further, the DID method assumes the compari-
son groups exhibit the same trend over time as the null
hypothesis. This assumption holds better when the base-
line difference is small [22]. This is the case for the cur-
rent study where no significant difference was observed
for both HbA1c value and the percentage of patients with
adequate glycemic control for the matched samples.
In this study of European patients with T2DM, the
majority of patients had not reached the goal of adequate
glycemic control with HbA1c < 6.5%. This might partially
be explained by the nature of the RECAP-DM sample
which comprised patients who failed metformin mono-
therapy. Existing studies based on RECAP-DM [15] also
showed that more and more patients used therapies with
insulin over time, which indicated intensification of the
medication treatment for this group of T2DM patients. It
is also likely that most of the patients in this sample had
moderate to severe T2DM. As indicated by our study
results, the proportions of patients with adequate glyce-
mic control decreased over time. This reflected the pro-
gressively deteriorating nature of T2DM, which has been
demonstrated in the literature [25,26]. Unfortunately, due
t o  l a c k  o f  da t a  w e  d i d  n o t  i n c l u d e  a n a l ys es  o n  d os a g e
information on the anti-hyperglycemic agents used after
the index date. This could have provided useful informa-
tion regarding differences in intensification regimens
between case and control cohorts. Nonetheless, the sub-
optimal glycemic control seen in CVD patients could also
have resulted from physicians' fear of increased mortality
Figure 2 Glycemic control over time.
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Baseline Clinical Information
HbA1c (%) 8.1 (1.3) 8.0 (1.4) 0.69 8.06 (1.26) 8.05 (1.39) 0.96
With HbA1c < 6.5% 5.2% 8.3% 0.037 5.1% 7.6% 0.14
Body mass index (kg/m2) 31.7 (8.2) 31.9 (6.2) 0.60 31.7 (6.6) 31.7 (6.7) 0.94
Physician specialty
Endocrinologists/Diabetologists 40.6% 40.6% 0.99 40.6% 41.1% 0.89
General practitioners/Internists 59.4% 59.4% 59.4% 58.9%
Duration of metformin use (years) 3.0 (2.9) 2.8 (2.5) 0.15 2.9 (2.7) 2.8 (2.5) 0.60
Note: CVD: cardiovascular diseases; S.D.: standard deviation.
Table 1: Patients characteristics by cardiovascular diseases at baseline (before and after propensity score 1:1 matching) (Continued)Fu et al. Cardiovascular Diabetology 2010, 9:15
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Table 2: Impact of pre-existing cardiovascular diseases on adequate glycemic control
Logistic regressions on percentage of patients with HbA1c < 6.5%
Variable Odds Ratio 95% confidence intervals P-value
With CVD vs. without CVD 0.62 0.46, 0.82 0.001
Time indicators
<1 year from index 6.21 3.61, 10.70 <0.001
1-2 years from index 6.39 3.72, 10.98 <0.001
2-3 years from index 6.69 3.81, 11.75 <0.001
3-4 years from index 7.66 4.24, 13.87 <0.001
>= 4 years from index 5.62 3.02, 10.46 <0.001
Variable Odds Ratio 95% confidence intervals P-value
With CVD vs. without CVD 0.62 0.46, 0.82 0.001
Study period vs. baseline 6.47 3.71, 11.29 <0.001
Years after the index 1.00 0.92, 1.10 0.96
Linear regressions on HbA1c (%)
Variable Coefficient 95% confidence intervals P-value
With CVD vs. without CVD 0.02 -0.10, 0.14 0.75
Time indicators
<1 year from index -0.80 -0.97, -0.62 <0.001
1-2 years from index -0.78 -0.96, -0.60 <0.001
2-3 years from index -0.76 -0.96, -0.57 <0.001
3-4 years from index -0.88 -1.07, -0.68 <0.001
>= 4 years from index -0.84 -1.07, -0.60 <0.001Fu et al. Cardiovascular Diabetology 2010, 9:15
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Variable Coefficient 95% confidence intervals P-value
With CVD vs. without CVD 0.02 -0.10, 0.14 0.75
Study period vs. baseline -0.78 -0.97, -0.59 <0.001
Years after the index -0.01 -0.05, 0.03 0.65
Note: CVD: cardiovascular diseases. Other controlled covariates in the regression analyses: concurrent treatment of the HbA1c measurement 
(metformin+SU combination therapy, metformin+glitazones combination therapy, SU monotherapy, glitazones monotherapy, metformin 
monotherapy, any therapies with insulin), index SU vs. glitazones, age, gender, Caucasian, duration of diabetes, never used alcohol, physical 
activity, country, BMI, physician specialty.
Table 2: Impact of pre-existing cardiovascular diseases on adequate glycemic control (Continued)
risk, which was observed in the ACCORD trial [13].
Additionally, using the interaction terms in the regression
analysis, we planned to test whether or not the HbA1c of
patients with CVD tended to deteriorate more quickly
than the HbA1c of patients without CVD. The results
indicated that the differential effect among our sample
was not statistically significant.
Due to the 1:1 propensity score matching, the final
sample (N = 788) was considerably reduced from the
original (N = 1942). A sensitivity analysis with propensity
score 1:3 matching with replacement was conducted (N =
1620) and the results were similar. We decided to use the
1:1 matching as our primary analysis because of the
greater internal validity of the design. Further, an alterna-
tive approach using last observation carried forward was
adopted as a sensitivity analysis, and similar results were
found. It is also worth noting that we applied a multiple
imputation procedure to impute the missing values of
each covariate. Sensitivity analysis excluding patients
with missing data was conducted (complete case analysis)
and as expected, the regression results were numerically
similar but non-significant, which was likely due to the
smaller sample size (N = 430).
Although a noteworthy difference in adequate glycemic
control was identified between T2DM patients with and
without pre-existing CVD, this study has several limita-
tions. First, this group of selected patients all had SU or
PPARγ agonist added to metformin monotherapy, and
they were recruited through their physicians who had
agreed to participate in the RECAP-DM study. These
physicians may be more motivated due to their willing-
ness to participate and their patients may not represent
the overall population of patients with T2DM in Europe.
Second, the CVD status was collected at baseline.
Patients without CVD before the index date may develop
CVD over time, which leads to potential misclassification
of the CVD status. Nevertheless, this effect can only
lessen the potential difference to be identified. With a sig-
nificant finding at present, the true difference in glycemic
control in those with and without pre-existing CVD
would have been larger if the potential misclassifications
were to be considered. Third, the biochemical marker of
microalbuminuria was not collected in the baseline
period. Given that T2DM patients are at significantly
increased risk of cardiovascular events [27], it would have
been important to control for other key risk factors for
CVD such as microalbuminuria. Fourth, as is typical with
any observational study, there may have been other unob-
served confounding factors not available in the data (e.g.,
other comorbid conditions) that could have led to resid-
ual confounding.
Conclusions
Based on a seven-country European sample, we found
that T2DM patients with pre-existing CVD tended to
have poorer glycemic control than those without pre-
existing CVD, all other factors being equal. This implies a
need for building awareness, education, and novel effec-
tive (or more aggressive) treatments for T2DM patients
with CVD. Current treatments may not be adequate in
this population. It is widely recognized that achieving
specific glycemic goals in patients with diabetes can sub-
stantially reduce diabetes-related complications. Since
p a t i e n t s  w i t h  p r e - e x i s t i n g  C V D  h a v e  a  h i g h e r  r i s k  o f
future diabetes-related complications, clinicians may
want to pay more attention to glycemic control in these
high risk patients.
Competing interests
AZF received research grant support from Merck & Co., Inc. for this study. YQ,
LR, DDY, and PM are employed by and are share holders of Merck & Co., Inc.
Authors' contributions
All authors contributed to the design of this study. AZF and PM performed the
statistical analyses. All authors contributed to the interpretation of the study
results and writing process, and approved the final manuscript.
Author Details
1Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, 
Ohio, USA and 2Global Outcomes Research, Merck & Co., Inc., Whitehouse 
Station, New Jersey, USA
Received: 22 February 2010 Accepted: 21 April 2010 
Published: 21 April 2010
This article is available from: http://www.cardiab.com/content/9/1/15 © 2010 Fu et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cardiovascular Diabetology 2010, 9:15Fu et al. Cardiovascular Diabetology 2010, 9:15
http://www.cardiab.com/content/9/1/15
Page 9 of 9
References
1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from 
coronary heart disease in subjects with type 2 diabetes and in 
nondiabetic subjects with and without prior myocardial infarction.  N 
Engl J Med 1998, 339:229-234.
2. Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL: Postchallenge 
hyperglycemia and mortality in a national sample of U.S. adults.  
Diabetes Care 2001, 24:1397-1402.
3. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, 
Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in 
patients with unstable angina and non-Q wave myocardial infarction: 
results of the Oasis Registry.  Circulation 2000, 102:1014-1019.
4. Diabetes Control and Complications Trial (DCCT) Research Group: Effect 
of intensive diabetes management on cardiovascular events and risk 
factors in the diabetes control and complications trial.  Am J Cardiol 
1995, 75:894-903.
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose 
control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33).  Lancet 1998, 352:837-853.
6. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, 
Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the 
progression of diabetic microvascular complications in Japanese 
patients with non-insulin dependent diabetes mellitus: a randomized 
prospective 6-year study.  Diabetes Res Clin Pract 1995, 28:103-117.
7. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, 
Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular 
disease in diabetes mellitus.  Ann Intern Med 2004, 141:421-431.
8. Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, 
Diem P: Glycemic control and cardiovascular disease in types 1 and 2 
diabetes mellitus: Meta-analysis of randomized trials.  Am Heart J 2006, 
152:27-38.
9. Gerstein HC, Pogue J, Mann JF, Lonn E, Dagenais GR, McQueen M, Yusuf S, 
HOPE investigators: The relationship between dysglycaemia and 
cardiovascular and renal risk in diabetic and non-diabetic participants 
in the HOPE study: a prospective epidemiological analysis.  
Diabetologia 2005, 48:1749-1755.
10. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, 
Erqou S, Sattar N: Effect of intensive control of glucose on 
cardiovascular outcomes and death in patients with diabetes mellitus: 
a meta-analysis of randomised controlled trials.  Lancet 2009, 
373:1765-1772.
11. Kauffman AB, Delate T, Olson KL, Cymbala AA, Hutka KA, Kasten SL, 
Rasmussen JR: Relationship between haemoglobin A1C values and 
recurrent cardiac events: A retrospective, longitudinal cohort study.  
Clin Drug Investig 2008, 28:501-507.
12. Cefalu WT: Glycemic targets and cardiovascular disease.  N Engl J Med 
2008, 358:2633-2635.
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein 
HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, 
Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, 
Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes.  
N Engl J Med 2008, 358:2545-2559.
14. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, 
Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet 
P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, 
Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: 
Intensive blood glucose control and vascular outcomes in patients 
with type 2 diabetes.  N Engl J Med 2008, 358:2560-2572.
15. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D: 
Glycaemic control among patients with type 2 diabetes mellitus in 
seven European countries: findings from the Real-Life Effectiveness 
and Care Patterns of Diabetes Management (RECAP-DM) study.  
Diabetes Obes Metab 2008, 10(Suppl 1):8-15.
16. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin 
D: Hypoglycaemic symptoms, treatment satisfaction, adherence and 
their associations with glycaemic goal in patients with type 2 diabetes 
mellitus: findings from the Real-Life Effectiveness and Care Patterns of 
Diabetes Management (RECAP-DM) Study.  Diabetes Obes Metab 2008, 
10(Suppl 1):25-32.
17. International Diabetes Federation: Clinical guidelines task force: global 
guideline for type 2 diabetes.  2005 [http://www.idf.org/webdata/docs/
IDF%20GGT2D.pdf].
18. Fu AZ, Li L: Thinking of having a higher predictive power for your first-
stage model in propensity score analysis? Think again.  Health Serv 
Outcomes Res Method 2008, 8:115-117.
19. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T: 
Variable selection for propensity score models.  Am J Epidemiol 2006, 
163:1149-1156.
20. Parsons LS: Performing a 1:N case-control match on propensity score.  
Proceedings of the 29th SAS Users Group International (SUGI) conference, 2004 
:165-29.
21. Athey S, Imbens GW: Identification and inference in nonlinear 
difference-in-differences models.  Econometrica 2006, 74:431-497.
22. Fu AZ, Dow WH, Liu GG: Propensity score and difference-in-difference 
methods: a study of second-generation antidepressant use in patients 
with bipolar disorder.  Health Serv Outcomes Res Method 2007, 7:23-38.
23. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes 
mellitus: blood pressure goals, choice of agents, and setting priorities 
in diabetes care.  Ann Intern Med 2003, 138:593-602.
24. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent 
cardiovascular disease in patients with type 2 diabetes mellitus.  Am J 
Med 2001, 111:633-42.
25. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, 
sulfonylurea, metformin, or insulin in patients with type 2 diabetes 
mellitus: progressive requirement for multiple therapies (UKPDS 49). 
UK Prospective Diabetes Study (UKPDS) Group.  JAMA 1999, 
281:2005-2012.
26. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC: Pancreatic beta-
cell mass in European subjects with type 2 diabetes.  Diabetes Obes 
Metab 2008, 10(Suppl 4):32-42.
27. Brown WV: Microvascular complications of diabetes mellitus: renal 
protection accompanies cardiovascular protection.  Am J Cardiol 2008, 
102:10L-13L.
doi: 10.1186/1475-2840-9-15
Cite this article as: Fu et al., Pre-existing cardiovascular diseases and glyce-
mic control in patients with type 2 diabetes mellitus in Europe: a matched 
cohort study Cardiovascular Diabetology 2010, 9:15